Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbamoylcholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 8/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.95 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.95 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.95 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.95 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.95 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.95 |
| ▸ | HTR1A | P08908 | 2/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.60 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamoylcholine SCHEMBL21067459 | 1.00 | CHRM1 (0.95) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL29167697 | 0.98 | CHRM1 (0.91) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL547970 | 0.98 | CHRM5 (0.95) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL21433743 | 0.98 | CHRM1 (0.91) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL8657363 | 0.98 | CHRM1 (0.91) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL1873894 | 0.98 | CHRM1 (0.91) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL9792915 | 0.98 | CHRM1 (0.91) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL2406725 | 0.98 | CHRM1 (1.00) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL2792 | 0.98 | CHRM1 (1.00) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Carbamoylcholine SCHEMBL27544830 | 0.96 | CHRM5 (0.91) | CHRM1CHRM3CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269330-A | Transdermal drug delivery patch, drug delivery system, and drug delivery method | 帕斯帕特技术有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6462016-B1 | IN CERTAIN MAMMAL TISSUE CULTURE CELLS, THE PRODUCTION OF CYCLIC ADENOSINE 3',5'-MONOPHOSPHORIC ACID IS ENHANCED BY MAXADILAN; CORRELATION BETWEEN BINDING INHIBITION, CAMP PRODUCTION AND ERYTHEMA FORMATION ABILITY | SHISEIDO COMPANY, LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| US-4459309-A | Compositions and methods of lowering intraocular pressure in the hypertensive mammalian eye | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1984-07-10 | — | — | US | disclosed |
| US-4377704-A | BRONCHODILATOR, ANTIAGGLOMERANT AGENTS | SANOFI (FR) | 1983-03-22 | — | — | US | disclosed |
| EP-0051604-A1 | COMPOSITIONS AND METHODS OF LOWERING INTRAOCULAR PRESSURE IN THE HYPERTENSIVE MAMMALIAN EYE | CHIOU, George C.Y. (US) | 1982-05-19 | — | — | EP | disclosed |
| WO-1981003123-A1 | COMPOSITIONS AND METHODS OF LOWERING INTRAOCULAR PRESSURE IN THE HYPERTENSIVE MAMMALIAN EYE | CHIOU G | 1981-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | CHRM3 1417/4885CHRM1 3077/4885CHRM2 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.